Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life

Vaccine

Volumn 18, Issue 9-10, 1999, Pages 947-954

  Kanra, Güler ^a   Silier, Thomas ^b   Yurdakök, Kadriye ^a   Yavuz, Tuna ^c   Baskan, Sevgi ^d   Ulukol, Betül ^d   Ceyhan, Mehmet ^a   Özmert, Elif ^a   Türkay, Fikri ^e   Pehlivan, Tamer ^e  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Department of Clinical Development ^*  (France)

^c Gülveren Child Center   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

^e Pasteur Merieux Connaught   (Turkey)

Author keywords

Antibodies, bacterial; Antibodies, viral; combined; Diphtheria tetanus pertussis vaccines; Haemophilus vaccines; Hepatitis B vaccines; Infants; Vaccines

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; POLIOMYELITIS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION;

DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; TURKEY; VACCINES, COMBINED; VACCINES, SYNTHETIC; WORLD HEALTH ORGANIZATION;

EID: 0032753936     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00331-X     Document Type: Article

References (43)

1. Fine P.E.M., Clarkson J.A. Reflections on the efficacy of pertussis vaccines. Rev. Infect. Dis. 9:1987;866-883.
2. Cherry J.D. The epidemiology of pertussis and pertussis immunization in the United States; a comparative study. Curr. Probl. Pediatr. 14:1984;1-78.
3. Cherry J.D., Brunell P.A., Golden G.S., Karzon D.T. Report of the Task Force on pertussis and pertussis immunization. Pediatrics. 81:1988;S939-944.
4. Romanus V., Jonsell R., Bergquist S.O. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr. Infect. Dis. J. 6:1987;364-371.
5. Cody C.L., Baraff L.J., Cherry J.D., Marcy S.M., Manclark C.R. Nature and rates of adverse reactions associated with DTP and DT immunization in infants and children. Pediatrics. 68:1981;650-660.
6. Barkin R.M., Pichichero M.E. Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products. Pediatrics. 63:1979;256-260.
7. Oda M., Cowell J.L., Burstyn D.G., Manclark C.R. Protective activities of filamentous hemagglutinin and lymphocytosis-promoting factor of Bordetella pertussis in mice. J. Infect. Dis. 150:1984;823-833.
8. Sato H., Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin and filamentous hemagglutinin, with mouse protectivity in an intracerebral of aerosol challenge system. Infec. Immun. 46:1994;415-421.
9. Pichichero M.E., Badgett J.T., Rodgers G.C. Jr, McLinns S., Trevino-Scatterday B., Nelson J.D. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18 and 24 month old children. Pediatr. Infect. Dis. J. 6:1987;352-363.
10. Edwards K.M., Bradley R.B., Decker M.D., Palmer P.S., Van Savage J., Taylor J.C., et al. Evaluation of a new highly purified pertussis vaccine in infants and children. J. Infect. Dis. 160:1989;832-837.
11. Auerbach B.S., Wilson M.E., Lake A.M., Deforest A., Steinhoff M., Halsey N.A. The acellular pertussis Vaccine Study Team: dose-response to acellular pertussis vaccine and comparison with whole-cell pertussis vaccine at 15-24 months and 4-6 years of age. Vaccine. 10:1992;14-20.
12. Eskola J., Kayhty H., Gordon L.K., Hovi T., Stenvik M., Ronnberg P.R., et al. Simultaneous administration of Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine with routine diphtheria-tetanus-pertussis and inactivated poliovirus vaccination of childhood. Pediatr. Infect. Dis. J. 7:1988;480-484.
13. Barra A., Dagan R., Preudhomme J.L., Bajard A., Danve B., Fritzell B. Characterization of the serum antibody response induced by Haemophilus influenzae type b tetanus protein-conjugate vaccine in infants receiving a DTP-combined vaccine from 2 months of age. Vaccine. 11:1993;1003-1006.
14. Clemens J.D., Ferreccio C., Levine M.M., Horwitz I., Rao M.R., Edwards K.M., Fritzell B. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA. 267:1992;673-678.
15. World Health Organisation. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull. WHO. 66:1988;443-455.
16. Universal hepatitis B immunization. Pediatrics. 89:1992;795-800.
17. Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly. Rep. 40:1991;1-25.
18. Granström M., Granström G., Gillenius P., Askelof P. Neutralization antibodies to pertussis toxin in whooping cough. J. Infect. Dis. 151:1985;646-649.
19. Manclarck D.R., Meade B.D., Burstyn D.G. Serological responses to Bordatella pertussis. Rose N.R., Friedman H., Fahey J.L. Manual of clinical laboratory immunology. 3rd ed. 1986;388-394 American Society for Microbiology, Washington DC.
20. Camargo M.E., Silveira L., Furuta J.A., Oliveira E.P., Germek O.A. Immunoenzymatic assay of antidiphtheria toxin antibodies in human sera. J. Clin. Microbiol. 20:1984;772-774.
21. Melville-Smith M.E., Seagroatt V.A., Watkins J.T. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J. Biol. Stand. 11:1983;137-144.
22. Grenier B., Hamza B., Biron G., Xueref C., Viarme F., Rouminatzeff M. Seroimmunity following vaccination in infants by an inactivated poliovirus preparation on Vero cells. Rev. Infect. Dis. 6:(2):1984;545-547.
23. Greenwood F.C., Hunter W.M. The preparation of 131-iodine-labelled human growth hormone of high specific radioactivity. Biochem. J. 89:1963;114-123.
24. Carlsson R.M., Claesson B.A., Selstam U., Fagerlund E., Granstrom M., Blondeau C., Hoffenbach A. Safety and immunogenicity of a combined diphtheria, tetanus, acellular pertussis-inactivated polio vaccine- Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr. Infect. Dis. J. 17:1998;1026-1033.
25. Hoppenbrouwers K., Lagos R., Swennen B., Ethevenaux C., Knops J., Levine M.M., Desmyter J. Safety and immunogenicity of an Haemophilus influnzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual chamber syringe to infants in Belgium and Chile. Vaccine. 16:1998;921-927.
26. Lagos R., Kotloff K.L., Hoffenbach A., San Martin O., Abrego P., Ureta A.M., et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six month-old Chilean infants. Pediatr. Infect. Dis. J. 17:1998;294-304.
27. Hoppenbrouwers K., Kanra G., Roelants M., Ceyhan M., Vandermeulen C., Yurdakök K., et al. Priming effect, immunogenicity and safety of an Haemophilus influnzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine. 17:1999;875-886.
28. Kanra G., Yurdakök K., Ceyhan M., Özmert E., Türkay F., Pehlivan T. Immunogenicity and safety of Haemophilus influenzae type b capsular polysaccharide tetanus conjugate vaccine (PRP-T) presented in a dual chamber syringe with DTP. Acta Paediatr. Japan. 39:1997;676-680.
29. King G.E., Hadler S.C. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr. Infect. Dis. J. 13:1994;394-407.
30. Dagan R., Botujansky C., Watemberg N., Arbelli Y., Belmaker I., Ethevenaux C., Fritzell B. Safety and immunogenicity in young infants of Haemophilus b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Pediatr. Infect. Dis. J. 13:1994;356-362.
31. Ferreccio C., Clemens J., Avendano A., Horwitz I., Flores C., Avila L. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr. Infect. Dis. J. 10:1991;764-771.
32. Simondon F., Preziosi M.P., Yam A., Kane C.T., Chabirand L., Heman I., et al. A randomized, double-blind trial comparing a two component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 15:1997;1606-1612.
33. Plotkin S.A., Cadoz M. Acellular vaccine efficacy trials. Pediatr. Infect. Dis. J. 16:1997;913-915.
34. Plotkin S.A., Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatr. Infect. Dis. J. 16:1997;508-517.
35. Eskola J., Ölander R-M., Hovi T., Litmanen L., Peltola S., Käyhty H. Randomized trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet. 348:1996;1688-1692.
36. Schmitt H.J. Immunogenicity and reactogenicity of two Hib tetanus conjugate vaccines administered by reconstituting with DTPa or given as separate injections. Proceedings of the 35th Interscience Conference on Antimicrobial agents and Chemotherapy. Abstr G63. San Francisco, CA, USA. 1995.
37. Schmitt H.J., Zepp F., Muschenborn S., Sumenicht G., Schuid A., Beutel K., et al. Immunogenecity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered seperately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur. J. Pediatr. 157:1998;208-214.
38. Bell F., Heath P., Shackley F., Mac Lennan J., Shearstone N., Diggle L., et al. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). Vaccine. 16:1998;637-642.
39. Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee. Update on hepatitis B prevention. Morbid. Mortal. Wkly. Rep. 36:1987;353-360, 366.
40. Seto D., Diwan A., Helsley T., Calandra G., Miller W. Hepatitis B vaccine alternative vaccination schedules in healthy babies of non-carrier mothers. Proceedings of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr 1104. Chicago, IL, USA. 1991.
41. Keyserling H.L., West D.J., Hesley T.M., Bosley C., Wiens B.L., Calandra G. Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve or fifteen months of age. J. Pediatr. 125:1994;67-69.
42. West D.J., Calandra G., Halsley T.M., Ioli V., Miller W.J. Control of hepatitis B through routine immunisation of infants: the need for flexible schedules and new combination formulations. Vaccine. 11:(1):1993;S21-S22.
43. Greenberg D.P., Vadheim C.M., Marcy S.M., Partridge S., Jing J., Chiu C.Y., et al. The Kaiser-UCLA Vaccine Study Group. Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2,4 and 6 months of age. Vaccine. 14:1996;811-816.